Download presentation
Presentation is loading. Please wait.
1
EHL Technologies in Hemophilia Care
3
Background
4
PEGylation of Factor VIII
5
Fc Fusion of Factor VIII
6
Immunogenicity of Factor VIII
7
Fc-Dependent Immunomodulatory Effector Pathways
8
The Role of Regulatory T Cells
9
Immunomodulatory Effect of Fc
10
Individualizing Therapy in Hemophilia Care
11
Pharmacokinetic Response to Factor VIII Varies Between Patients
12
Treatment Targets
13
Parameters for Selecting the Right Treatment
14
Key Advantages of New Agents With EHL
15
Pivotal Clinical Trials of EHL Factor VIIIs
16
Dosing Regimens in Prophylactic Trial Arms
17
Results: Median ABR
18
Results: Zero ABR
19
Effect of Duration of Treatment on ABR and QoL
20
Safety Outcomes
21
Key Messages From Trials
22
Key Messages From Trials (cont)
23
Switching From Conventional Therapy to EHL Agents
24
Switching From Conventional Therapy to EHL Agents (cont)
25
Summary
26
Abbreviations
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.